Inside the AD Pipeline: Zai Lab’s Long-acting ZL-1503 Shows Promise in First-in-human Study

One dose of ZL-1503, a long-acting interleukin (IL)-13/IL-31 receptor alpha (Rα) bispecific antibody, produced near-complete inhibition of IL-13-stimulated pSTAT6 in healthy volunteers for at least three months across dose levels, according to first-in-human results from the single-ascending-dose portion of a Phase 1/1b trial.